| Literature DB >> 31172682 |
Hongyan Zhang1, Dongwang Qi1, Hongfei Gu2, Tao Wang2, Yanan Wu3,4,5, Jingyan Li1, Jingxian Ni3,4,5, Jie Liu3,4,5, Jun Tu3,4,5, Xianjia Ning3,4,5, Jinghua Wang3,4,5.
Abstract
AIMS/Entities:
Keywords: Diabetes mellitus; Epidemiology; Trends
Mesh:
Substances:
Year: 2019 PMID: 31172682 PMCID: PMC6944834 DOI: 10.1111/jdi.13095
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Description of demographic characteristics among all participants in two surveys
| Characteristics | Total | Men | Women | |||
|---|---|---|---|---|---|---|
| 1992 | 2011 | 1992 | 2011 | 1992 | 2011 | |
| Participants (%) | 1,091 | 2,338 | 423 | 938 | 668 | 1,400 |
| Mean age (SD) | 45.95 (9.56) | 54.52 (8.20) | 47.36 (9.66) | 54.72 (8.41) | 45.05 (9.39) | 54.39 (8.06) |
| Age group, years (%) |
|
|
| |||
| 35–44 | 580 (53.2) | 351 (15.0) | 200 (47.3) | 140 (14.9) | 380 (56.9) | 211 (15.1) |
| 45–54 | 238 (21.8) | 624 (26.7) | 99 (23.4) | 235 (25.1) | 139 (20.8) | 389 (27.8) |
| 55–64 | 273 (25.0) | 1,363 (58.3) | 124 (29.3) | 563 (60.0) | 149 (22.3) | 800 (57.1) |
| Education level (%) |
|
|
| |||
| 0 year | 280 (25.7) | 215 (9.2) | 58 (13.7) | 19 (2.0) | 222 (33.2) | 196 (14.1) |
| 1–6 years | 444 (40.7) | 868 (37.2) | 167 (39.5) | 300 (32.0) | 277 (41.5) | 568 (40.7) |
| >6 years | 367 (33.6) | 1,250 (53.6) | 198 (46.8) | 619 (66.0) | 169 (25.3) | 631 (45.2) |
| Hypertension (%) | 512 (46.9) | 1,408 (60.3) | 200 (47.3) | 564 (60.3) | 312 (46.7) | 844 (60.3) |
| Diabetes (%) | 21 (1.9) | 254 (10.9) | 7 (1.7) | 98 (10.5) | 14 (2.1) | 156 (11.2) |
| Smoking (%) |
|
|
| |||
| Never | 808 (74.1) | 164 (30.1) | 165 (39.0) | 25 (7.3) | 643 (96.3) | 139 (69.2) |
| Ever | 5 (0.5) | 34 (6.2) | 5 (1.2) | 34 (9.9) | 0 | 0 |
| Current | 278 (25.5) | 347 (63.7) | 253 (59.8) | 285 (82.8) | 25 (3.7) | 62 (30.8) |
| Drinking (%) |
|
|
| |||
| Never | 859 (78.7) | 173 (37.6) | 204 (48.2) | 34 (12.6) | 655 (98.1) | 139 (72.8) |
| Ever | 0 | 12 (2.6) | 0 | 12 (4.5) | 0 | 0 |
| Current | 232 (21.3) | 275 (59.8) | 219 (51.8) | 223 (82.9) | 13 (1.9) | 52 (27.2) |
| BP (mmHg) | ||||||
| SBP | 132.39 (23.66) | 141.07 (22.05) | 131.90 (21.43) | 141.09 (21.39) | 132.70 (24.98) | 141.06 (22.48) |
| DBP | 83.83 (12.53) | 86.54 (13.00) | 84.23 (12.18) | 87.70 (13.50) | 83.59 (12.74) | 85.76 (12.61) |
| BP groups (%) |
|
|
| |||
| Normal | 594 (54.4) | 1,041 (44.5) | 231 (54.6) | 418 (44.6) | 363 (54.3) | 623 (44.5) |
| Stage I | 355 (32.5) | 807 (34.5) | 138 (32.6) | 307 (32.7) | 217 (32.5) | 500 (35.7) |
| Stage II | 74 (6.8) | 349 (14.9) | 25 (5.9) | 147 (15.7) | 49 (7.3) | 202 (14.4) |
| Stage III | 68 (6.2) | 141 (6.0) | 29 (6.9) | 66 (7.0) | 39 (5.8) | 75 (5.4) |
| BMI | 23.55 (3.19) | 25.34 (4.60) | 23.23 (2.80) | 25.04 (5.48) | 23.74 (3.41) | 25.54 (3.88) |
| BMI groups (%) |
|
|
| |||
| Normal | 658 (60.3) | 894 (38.2) | 281 (66.4) | 396 (42.2) | 377 (56.4) | 498 (35.6) |
| Overweight | 334 (30.6) | 952 (40.7) | 116 (27.4) | 377 (40.2) | 218 (32.6) | 575 (41.1) |
| Obesity | 99 (9.1) | 492 (21.0) | 26 (6.1) | 165 (17.6) | 73 (10.9) | 327 (23.4) |
| Laboratory examinations (mmol/L) | ||||||
| FPG | 4.64 (1.18) | 5.33 (1.65) | 4.75 (1.48) | 5.30 (1.59) | 4.57 (0.93) | 5.34 (1.68) |
| TC | 4.41 (1.11) | 4.78 (1.29) | 4.42 (1.09) | 4.70 (1.38) | 4.40 (1.12) | 4.83 (1.23) |
| TG | 1.30 (0.31) | 1.65 (0.76) | 1.31 (0.29) | 1.75 (0.58) | 1.30 (0.32) | 1.58 (1.03) |
†Indicated P < 0.001 compared between 1992 and 2011. BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; SBP, systolic blood pressure; SD, standard deviation; TC, total cholesterol; TG, triglyceride.
Trends in the sex‐specific prevalence, awareness, treatment and control rates of diabetes by age during 1991 to 2011
| Total | Men | Women | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 1992 | 2011 |
| 1992 | 2011 |
| 1992 | 2011 |
| |
| Prevalence | |||||||||
| 35–44 years | 1.2 (0.3–2.1) | 4.8 (2.6–7.1) | 0.001 | 1.0 (0–2.4) | 6.4 (2.3–10.5) | 0.009 | 1.3 (0.2–2.5) | 3.8 (1.2–6.4) | 0.075 |
| 45–54 years | 2.9 (0.8–5.1) | 8.7 (6.4–10.9) | 0.003 | 2.0 (0–4.8) | 10.6 (6.7–14.6) | 0.008 | 3.6 (0.5–6.7) | 7.5 (4.8–10.1) | 0.112 |
| 55–64 years | 2.6 (0.8–5.2) | 13.5 (11.7–15.3) | <0.001 | 2.4 (0–5.2) | 11.4 (8.7–14.0) | 0.002 | 2.7 (0.1–5.3) | 14.9 (12.4–17.3) | <0.001 |
| Total | 1.9 (1.1–2.7) | 10.9 (9.6–12.2) | <0.001 | 1.7 (0.4–2.9) | 10.5 (8.5–12.4) | <0.001 | 2.1 (1.0–3.2) | 11.2 (9.6–12.9) | <0.001 |
| Awareness | |||||||||
| 35–44 years | 57.1 (53.0–61.1) | 17.6 (13.7–21.7) | 0.134 | 50.0 (43.0–57.0) | 50.0 (41.6–58.4) | 0.109 | 40.0 (35.1–44.9) | 12.5 (7.9–16.8) | 0.510 |
| 45–54 years | 14.3 (9.8–18.8) | 48.1 (44.1–52.0) | 0.121 | 0 | 56.0 (49.8–62.6) | 0.222 | 20.0 (13.4–26.9) | 41.4 (36.5–46.3) | 0.627 |
| 55–64 years | 57.1 (51.2–63.1) | 45.4 (42.8–48.1) | 0.705 | 33.3 (24.7–41.5) | 39.1 (35.0–43.1) | 1.000 | 75.0 (68.1–82.2) | 48.7 (45.3–52.2) | 0.365 |
| Total | 42.9 (40.0–45.8) | 44.1 (42.1–46.1) | 0.913 | 42.9 (38.1–47.5) | 41.8 (38.6–45.0) | 1.000 | 42.9 (39.2–46.7) | 45.5 (42.9–48.1) | 0.848 |
| Treatment | |||||||||
| 35–44 years | 25.0 (21.5–28.5) | 0 | 1.000 | 50.0 (43.0–57.0) | 0 | 1.000 | 0 | 0 | – |
| 45–54 years | 0 | 26.9 (23.1–30.0) | 1.000 | – | 21.4 (16.0–26.5) | – | 0 | 33.3 (28.7–38.1) | 1.000 |
| 55–64 years | 0 | 53.0 (50.3, 55.6) | 0.055 | 0 | 48.0 (43.8, 52.1) | 1.000 | 0 | 55.2 (51.8, 58.7) | 0.102 |
| Total | 11.1 (9.2, 13.0) | 45.5 (43.5–47.5) | 0.076 | 33.3 (28.8, 37.8) | 36.6 (33.5–39.7) | 1.000 | 0 | 50.7 (48.1–53.3) | 0.027 |
| Control | |||||||||
| 35–44 years | 25.0 (21.5–28.5) | – | – | 50.0 (43.0–57.0) | – | – | – | – | – |
| 45–54 years | – | 14.3 (11.5–17.0) | – | – | 33.3 (27.1– 39.3) | – | – | – | – |
| 55–64 years | – | 50.0 (47.3–52.7) | – | – | 50.0 (45.9–54.1) | – | – | 50.0 (46.5–53.5) | – |
| Total | 11.1 (9.2–13.0) | 45.1 (43.1–47.1) | 0.072 | 33.3 (28.8–37.8) | 46.7 (43.5–49.9) | 1.000 | – | 44.4 (41.8–47.0) | – |
Data is presented as the rate and the 95% confidence interval.
Trends in the sex‐specific prevalence, awareness, treatment and control rates of diabetes by education levels during 1991 to 2011
| Total | Men | Women | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 1992 | 2011 |
| 1992 | 2011 |
| 1992 | 2011 |
| |
| Prevalence | |||||||||
| 0 year | 2.6 (0.7–4.3) | 4.8 (1.8–7.5) | 0.193 | 3.3 (0, 8.3) | 2.2 (0–5.5) | 1.000 | 2.2 (0.3–4.2) | 5.0 (2.0–8.2) | 0.118 |
| 1–6 years | 2.1 (0.7–3.3) | 11.2 (9.1–13.3) | <0.001 | 1.9 (0–3.8) | 10.4 (6.9–13.8) | 0.001 | 1.2 (0–2.3) | 9.5 (7.1–11.9) | <0.001 |
| >6 years | 1.7 (0.3–2.9) | 6.7 (5.3–8.0) | <0.001 | 0.3 (0–1.5) | 8.4 (6.2–10.6) | <0.001 | 3.2 (0.4–5.5) | 7.0 (5.0–9.0) | 0.053 |
| Awareness | |||||||||
| 0 year | 1.2 (0–2.3) | 2.7 (0.6–5.0) | 1.000 | 0.3 (0–1.6) | 2.2 (0–22.6) | 1.000 | 1.3 (0–2.9) | 2.6 (0.3–4.8) | 1.000 |
| 1–6 years | 0.6 (0–1.4) | 2.9 (1.8–4.0) | 1.000 | 0.6 (0–1.8) | 2.9 (1.1–4.9) | 1.000 | 0.3 (0–1.1) | 2.9 (1.5–4.2) | 1.000 |
| >6 years | 0.1 (0–0.2) | 2.7 (1.8–3.5) | 1.000 | 0.3 (0–1.5) | 3.4 (2.0–4.8) | 1.000 | 0 | 1.7 (0.7–2.8) | 1.000 |
| Treatment | |||||||||
| 0 year | 0 | 8.2 (4.6–12.1) | 1.000 | 0 | 10.9 (0–25.7) | 1.000 | 0 | 7.5 (3.9–11.4) | 1.000 |
| 1–6 years | 0 | 16.1 (13.7–18.6) | 1.000 | 0 | 5.5 (2.8–7.9) | 1.000 | 0 | 17.7 (14.5–20.7) | 1.000 |
| >6 years | 25.6 (21.1–30.1) | 17.6 (15.4–19.6) | 1.000 | 25.4 (19.1–31.4) | 17.9 (14.9–21.0) | 1.000 | 0 | 14.7 (12.0–17.5) | 1.000 |
| Control | |||||||||
| 0 year | 0 | 10.9 (6.9–15.4) | 1.000 | 0 | 0 | 1.000 | 0 | 12.7 (8.0–17.5) | 1.000 |
| 1–6 years | 0 | 5.7 (4.1–7.2) | 1.000 | 0 | 5.9 (3.3–8.7) | 1.000 | 0 | 5.6 (3.7–7.5) | 1.000 |
| >6 years | 25.6 (21.1–30.1) | 12.6 (10.7–14.4) | 1.000 | 25.4 (19.1–31.4) | 17.8 (14.8–20.8) | 1.000 | 0 | 3.2 (1.8–4.5) | 1.000 |
Data is presented as the rate and the 95% confidence interval.
Trends in the sex‐specific prevalence, awareness, treatment and control rates of diabetes by blood pressure levels during 1991 to 2011
| Total | Men | Women | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 1992 | 2011 |
| 1992 | 2011 |
| 1992 | 2011 |
| |
| Prevalence | |||||||||
| Normal | 1.9 (0.8–2.9) | 5.6 (4.2–7.0) | <0.001 | 2.3 (0.3–4.1) | 6.8 (4.3–9.1) | 0.012 | 1.6 (0.3–3.0) | 4.0 (2.5–5.6) | 0.041 |
| Stage I | 2.2 (0.7–3.8) | 10.1 (8.1–12.3) | <0.001 | 0.7 (0–2.2) | 13.1 (9.2–16.9) | <0.001 | 2.6 (0.6–5.0) | 6.9 (4.6–9.0) | 0.031 |
| Stage II | 4.4 (0–8.7) | 10.8 (7.6–14.2) | 0.071 | 3.6 (0–12.3) | 7.9 (3.7–12.6) | 0.695 | 4.1 (0–9.8) | 9.4 (5.3–13.5) | 0.386 |
| Stage III | 2.1 (0–4.4) | 11.2 (6.0–16.6) | 0.014 | 1.2 (0–2.5) | 8.5 (2.0–16.2) | 0.173 | 1.8 (0–7.8) | 12.3 (4.5–.19.5) | 0.160 |
| Awareness | |||||||||
| Normal | 1.1 (0. 3–2.0) | 1.6 (0. 9–2.4) | 1.000 | 1.3 (0–2.8) | 2.1 (0.8–3.6) | 1.000 | 1.1 (0–2.2) | 0.9 (0.1–1.5) | 1.000 |
| Stage I | 0. 9 (0–1.8) | 3.7 (2.4–5.0) | 1.000 | 0 | 5.6 (3.0–8.1) | 1.000 | 1.1 (0–2.2) | 2.9 (1.5–4.5) | 1.000 |
| Stage II | 0 | 4.1 (1.9–6.1) | 1.000 | 0 | 4.0 (0.8–7.3) | 1.000 | 0 | 3.9 (1.2–6.7) | 1.000 |
| Stage III | 0 | 4.1 (0.9–7.6) | 1.000 | 0 | 3.5 (0–7.3) | 1.000 | 0 | 4.4 (0–8.5) | 1.000 |
| Treatment | |||||||||
| Normal | 25.5 (22.1–29.1) | 21.1 (18.6–23.6) | 0.612 | 25.4 (19.9–31.2) | 22.5 (18.5–26.5) | 1.000 | 0 | 17.7 (14.8–20.8) | 1.000 |
| Stage I | 0 | 33.6 30.3–36.8) | 1.000 | 0 | 30.7 (25.4–35.8) | 1.000 | 0 | 15.2 (12.0–18.4) | 1.000 |
| Stage II | 0 | 13.9 (10.4–17.7) | 1.000 | 0 | 5.0 (1.3–8.2) | 1.000 | – | 16.1 (11.2–21.5) | – |
| Stage III | 0 | 4.9 (1.3–8.6) | 1.000 | 0 | – | – | – | 7.3 (0.9–12.4) | – |
| Control | |||||||||
| Normal | 25.5 (22.1–29.1) | 24.9 (22.3–27.6) | 1.000 | 25.4 (19.9–31.2) | 27.7 (23.4–32.1) | 1.000 | 0 | 5.8 (3.9–7.6) | 1.000 |
| Stage I | 0 | 6.4 (4.7–8.1) | 1.000 | 0 | 2.5 (0.8–4.4) | 1.000 | 0 | 7.3 (5.1–9.7) | 1.000 |
| Stage II | 0 | 7.3 (4.7–10.2) | 1.000 | 0 | 9.8 (4.7–14.3) | 1.000 | – | 6.5 (3.0–9.8) | – |
| Stage III | 0 | 6.5 (2.3–10.5) | 1.000 | 0 | – | – | – | 6.5 (0.9–12.4) | – |
Data is presented as the rate and the 95% confidence interval.
Trends in the sex‐specific prevalence, awareness, treatment and control rates of diabetes by body mass index during 1991 to 2011
| Total | Men | Women | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 1992 | 2011 |
| 1992 | 2011 |
| 1992 | 2011 |
| |
| Prevalence | |||||||||
| Normal | 2.3 (1.1–3.4) | 3.4 (2.3–4.7) | 0.208 | 2.0 (0.4–3.8) | 3.6 (1.7–5.4) | 0.284 | 2.1 (0.7–3.6) | 3.5 (1.8–5.0) | 0.171 |
| Overweight | 1.0 (0–1.9) | 9.4 (7.5–11.2) | <0.001 | 0.9 (0–2.6) | 11.6 (8.4–14.9) | <0.001 | 1.0 (0–2.2) | 6.5 (4.4–8.4) | 0.001 |
| Obesity | 4.2 (0.1–8.0) | 12.1 (9.3–15.1) | <0.001 | 2.2 (0–11.8) | 12.1 (7.1–17.2) | 0.081 | 5.2 (0.1–10.8) | 9.2 (6.0–12.3) | 0.764 |
| Awareness | |||||||||
| Normal | 1.1 (0.3–1.8) | 1.5 (0.8–2.4) | 1.000 | 1.5 (0–2.8) | 1.7 (0.5–3.1) | – | 1.2 (0–2.1) | 1.5 (0.5–2.7) | – |
| Overweight | 0.3 (0–0.9) | 3.4 (2.3–4.6) | 1.000 | 0 | 5.2 (3.0–7.6) | 1.000 | 0.4 (0–1.4) | 2.2 (1.0–3.5) | 1.000 |
| Obesity | 0 | 4.4 (2.6–6.3) | 1.000 | 0 | 3.0 (0.4–5.7) | 1.000 | 0 | 4.0 (1.8–6.1) | 1.000 |
| Treatment | |||||||||
| Normal | 12.8 (10.2–15.3) | 10.6 (8.6–12.7) | 1.000 | 25.4 (20.2–30.4) | 15.1 (11.6–18.7) | 1.000 | 0 | 8.8 (6.3–11.3) | 1.000 |
| Overweight | 0 | 20.2 (17.6–22.7) | 1.000 | 0 | 17.9 (14.1–21.9) | 1.000 | 0 | 19.8 (16.6–23.1) | 1.000 |
| Obesity | 0 | 14.1 (10.9–17.1) | 1.000 | 0 | 16.0 (10.1–21.4) | 1.000 | 0 | 13.3 (9.7–17.2) | 1.000 |
| Control | |||||||||
| Normal | 12.8 (10.2–15.3) | 8.1 (6.4–10.0) | 1.000 | 25.4 (20.2–30.4) | 6.5 (4.1–9.0) | 0.375 | 0 | 10.3 (7.6–12.9) | 1.000 |
| Overweight | 0 | 5.6 (4.1–7.0) | 1.000 | 0 | 3.9 (2.0–6.0) | 1.000 | 0 | 6.1 (4.1–8.0) | 1.000 |
| Obesity | 0 | 15.0 (11.9–18.2) | 1.000 | 0 | 35.6 (28.4–43.1) | 1.000 | 0 | 4.9 (2.5–7.2) | 1.000 |
Data is presented as the rate and the 95% confidence interval.